Works matching AU Cheah, Chan Y.

Results: 56
    1
    2

    Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

    Published in:
    EJHaem, 2024, v. 5, n. 2, p. 325, doi. 10.1002/jha2.870
    By:
    • Shaw, Briony;
    • Chung, Eliza;
    • Wellard, Cameron;
    • Yoo, Edward;
    • Bennett, Rory;
    • Birks, Callum;
    • Johnston, Anna;
    • Cheah, Chan Y;
    • Hamad, Nada;
    • Simpson, Jock;
    • Barraclough, Allison;
    • Ku, Matthew;
    • Viiala, Nicholas;
    • Ratnasingam, Sumita;
    • Armytage, Tasman;
    • Cochrane, Tara;
    • Chong, Geoffrey;
    • Lee, Denise;
    • Manos, Kate;
    • Keane, Colm
    Publication type:
    Article
    3
    4
    5
    6

    Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.

    Published in:
    American Journal of Hematology, 2016, v. 91, n. 9, p. 894, doi. 10.1002/ajh.24429
    By:
    • Cheah, Chan Y.;
    • Bröckelmann, Paul J.;
    • Chihara, Dai;
    • Moskowitz, Alison J.;
    • Engert, Andreas;
    • Jerkeman, Mats;
    • El-Galaly, Tarec C.;
    • Augustson, Bradley;
    • Vose, Julie;
    • Bartlett, Nancy L.;
    • Villa, Diego;
    • Connors, Joseph M.;
    • Feldman, Tatyana;
    • Pinnix, Chelsea C.;
    • Milgrom, Sarah A.;
    • Dabaja, Bouthaina;
    • Oki, Yasuhiro;
    • Fanale, Michelle A.
    Publication type:
    Article
    7
    8

    P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT.

    Published in:
    2023
    By:
    • Jurczak, Wojciech;
    • Luigi Zinzani, Pier;
    • Eyre, Toby A.;
    • Cheah, Chan Y.;
    • Ujjani, Chaitra S.;
    • Izutsu, Koji;
    • MA, Shuo;
    • Flinn, Ian;
    • Alencar, Alvaro J.;
    • Lewis, David;
    • Patel, Krish;
    • Maddocks, Kami;
    • Wang, Yucai;
    • Munir, Talha;
    • Zelenetz, Andrew D.;
    • Balbas, Minna;
    • Tsai, Donald E.;
    • Wang, Chunxiao;
    • Wang, Michael L.;
    • Shah, Nirav N.
    Publication type:
    Abstract
    9
    10
    11
    12
    13
    14
    15
    16
    17

    The utility and limitations of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 1, p. 49, doi. 10.3109/10428194.2014.910656
    By:
    • Cheah, Chan Y.;
    • Hofman, Michael S.;
    • Seymour, John F.;
    • Ritchie, David S.;
    • Dickinson, Michael;
    • Wirth, Andrew;
    • Prince, H. Miles;
    • Wolf, Max;
    • Januszcewicz, Elchanan H.;
    • Carney, Dennis A.;
    • Herbert, Kirsten E.;
    • Harrison, Simon J.;
    • Burbury, Kate L.;
    • Tam, Constantine S.
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic.

    Published in:
    Internal Medicine Journal, 2020, v. 50, n. 6, p. 667, doi. 10.1111/imj.14859
    By:
    • Di Ciaccio, Pietro;
    • McCaughan, Georgia;
    • Trotman, Judith;
    • Ho, Phoebe Joy;
    • Cheah, Chan Y.;
    • Gangatharan, Shane;
    • Wight, Joel;
    • Ku, Matthew;
    • Quach, Hang;
    • Gasiorowski, Robin;
    • Polizzotto, Mark N.;
    • Prince, Henry Miles;
    • Mulligan, Stephen;
    • Tam, Constantine S.;
    • Gregory, Gareth;
    • Hapgood, Greg;
    • Spencer, Andrew;
    • Dickinson, Michael;
    • Latimer, Maya;
    • Johnston, Anna
    Publication type:
    Article
    28

    Author reply.

    Published in:
    2019
    By:
    • Trotman, Judith;
    • Cheah, Chan Y.;
    • Marlton, Paula;
    • Opat, Stephen
    Publication type:
    Letter to the Editor
    29
    30
    31
    32

    Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.

    Published in:
    Acta Haematologica, 2025, v. 148, n. 2, p. 180, doi. 10.1159/000539587
    By:
    • Roeker, Lindsey E.;
    • Coombs, Catherine C.;
    • Shah, Nirav N.;
    • Jurczak, Wojciech;
    • Woyach, Jennifer A.;
    • Cheah, Chan Y.;
    • Patel, Krish;
    • Maddocks, Kami;
    • Wang, Yucai;
    • Zinzani, Pier Luigi;
    • Munir, Talha;
    • Koh, Youngil;
    • Thompson, Meghan C.;
    • Muehlenbein, Catherine E.;
    • Wang, Chunxiao;
    • Sizelove, Richard;
    • Abhyankar, Sarang;
    • Hasanabba, Safarulla;
    • Tsai, Donald E.;
    • Eyre, Toby A.
    Publication type:
    Article
    33
    34
    35
    36
    37

    Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.

    Published in:
    British Journal of Haematology, 2023, v. 201, n. 5, p. 865, doi. 10.1111/bjh.18704
    By:
    • Lim, Kenneth J. C.;
    • Di Ciaccio, Pietro;
    • Polizzotto, Mark N.;
    • Milliken, Sam;
    • Cochrane, Tara;
    • Goh, Zhong;
    • Shaw, Briony;
    • Perry, Evelyn;
    • Gilbertson, Michael;
    • Kermode, William;
    • Cheah, Chan Y.;
    • Latimer, Maya;
    • Hamad, Nada;
    • Ku, Matthew
    Publication type:
    Article
    38
    39
    40
    41
    42

    Dose adjusted- EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.

    Published in:
    British Journal of Haematology, 2017, v. 179, n. 3, p. 503, doi. 10.1111/bjh.14226
    By:
    • Chihara, Dai;
    • Westin, Jason R.;
    • Miranda, Roberto N.;
    • Cheah, Chan Y.;
    • Oki, Yasuhiro;
    • Turturro, Francesco;
    • Romaguera, Jorge E.;
    • Neelapu, Sattva S.;
    • Nastoupil, Lorreta J.;
    • Fayad, Luis E.;
    • Rodriguez, M. Alma;
    • Fowler, Nathan H.;
    • Orlowski, Robert Z.;
    • Wang, Michael;
    • Hagemeister, Fredrick B.;
    • Medeiros, L. Jeffrey;
    • Fanale, Michelle A.
    Publication type:
    Article
    43

    Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.

    Published in:
    British Journal of Haematology, 2016, v. 175, n. 5, p. 876, doi. 10.1111/bjh.14325
    By:
    • El ‐ Galaly, Tarec Christoffer;
    • Cheah, Chan Y.;
    • Hutchings, Martin;
    • Mikhaeel, Nabegh George;
    • Savage, Kerry J.;
    • Sehn, Laurie H.;
    • Barrington, Sally;
    • Hansen, Jakob W.;
    • Poulsen, Mette Ø.;
    • Smith, Daniel;
    • Rady, Kirsty;
    • Mylam, Karen J.;
    • Larsen, Thomas S.;
    • Holmberg, Staffan;
    • Juul, Maja B.;
    • Cordua, Sabrina;
    • Clausen, Michael R.;
    • Jensen, Kristina B.;
    • Bøgsted, Martin;
    • Johnsen, Hans E.
    Publication type:
    Article
    44
    45

    Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.

    Published in:
    British Journal of Haematology, 2016, v. 172, n. 1, p. 80, doi. 10.1111/bjh.13796
    By:
    • Chihara, Dai;
    • Cheah, Chan Y.;
    • Westin, Jason R.;
    • Fayad, Luis E.;
    • Rodriguez, Maria A.;
    • Hagemeister, Fredrick B.;
    • Pro, Barbara;
    • McLaughlin, Peter;
    • Younes, Anas;
    • Samaniego, Felipe;
    • Goy, Andre;
    • Cabanillas, Fernando;
    • Kantarjian, Hagop;
    • Kwak, Larry W.;
    • Wang, Michael L.;
    • Romaguera, Jorge E.
    Publication type:
    Article
    46
    47

    Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 370, doi. 10.1016/j.clml.2023.01.014
    By:
    • Goh, Zhong;
    • Latimer, Maya;
    • Lewis, Katharine L.;
    • Cheah, Chan Y.;
    • Ciaccio, Pietro Di;
    • Cushion, Tania;
    • Hawkes, Eliza A.;
    • Harrop, Sean;
    • Ku, Matthew;
    • Campbell, Ashlea;
    • Hamad, Nada;
    • Wood, Erica M.;
    • Chung, Eliza;
    • Chen, Pin-Yen;
    • Cochrane, Tara
    Publication type:
    Article
    48

    IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S404, doi. 10.1016/S2152-2650(21)01912-1
    By:
    • Ghosh, Nilanjan;
    • Zinzani, Pier Luigi;
    • Samaniego, Felipe;
    • Jurczak, Wojciech;
    • Derenzini, Enrico;
    • Reeves, James A.;
    • Knopinska-Posluszny, Wanda;
    • Cheah, Chan Y.;
    • Phillips, Tycel;
    • Lech-Maranda, Ewa;
    • Cheson, Bruce;
    • Calmi, Paolo;
    • Grosicki, Sebastian;
    • Leslie, Lori A.;
    • Chavez, Julio C.;
    • Fonseca, Gustavo;
    • Babu, Sunil;
    • Hodson, Daniel J.;
    • Shao, Spencer H.;
    • Burke, John M.
    Publication type:
    Article
    49

    CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S315, doi. 10.1016/S2152-2650(21)01746-8
    By:
    • Coombs, Catherine C.;
    • Pagel, John M.;
    • Shah, Nirav N.;
    • Lamanna, Nicole;
    • Lech-Maranda, Ewa;
    • Eyre, Toby A.;
    • Woyach, Jennifer A.;
    • Wierda, William G;
    • Cheah, Chan Y.;
    • Roeker, Lindsey;
    • Patel, Manish R.;
    • Fakhri, Bita;
    • Barve, Minal A.;
    • Tam, Constantine S.;
    • Lewis, David J.;
    • Gerson, James N.;
    • Alencar, Alvaro;
    • Taylor, Justin;
    • Abdel-Wahab, Omar;
    • Ghia, Paolo
    Publication type:
    Article
    50

    Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01537-8
    By:
    • Ghosh, Nilanjan;
    • Zinzani, Pier Luigi;
    • Samaniego, Felipe;
    • Jurczak, Wojciech;
    • Derenzini, Enrico;
    • Reeves, James A.;
    • Knopinska-Posluszny, Wanda;
    • Cheah, Chan Y.;
    • Phillips, Tycel;
    • Lech-Maranda, Ewa;
    • Cheson, Bruce;
    • Caimi, Paolo;
    • Grosicki, Sebastian;
    • Leslie, Lori A.;
    • Chavez, Julio C.;
    • Fonseca, Gustavo;
    • Babu, Sunil;
    • Hodson, Daniel J.;
    • Shao, Spencer H.;
    • Burke, John M.
    Publication type:
    Article